Immediate Management of Suspected DRESS Syndrome in a Patient on Divalproex and Brivaracetam
Immediately discontinue divalproex (valproic acid) and hospitalize the patient for close monitoring and supportive care, while continuing brivaracetam for seizure control. DRESS syndrome is a life-threatening hypersensitivity reaction that requires urgent intervention to prevent mortality from multi-organ failure.
Critical First Steps
Discontinue the Offending Agent
- Stop divalproex immediately 1. Valproic acid is a known, albeit rare, cause of DRESS syndrome 2, 3, 4, 5. The FDA label explicitly warns about allergic hypersensitivity reactions including fever, skin rash, hives, blistering and peeling of skin, and swelling 1.
- Continue brivaracetam for seizure control—there is no evidence linking brivaracetam to DRESS syndrome, and abrupt discontinuation of all antiepileptic drugs risks status epilepticus 1, 6.
Critical pitfall: Do not stop all medications simultaneously. Valproic acid is the likely culprit given its established association with DRESS, while brivaracetam can be safely continued for seizure management.
Immediate Hospitalization
Admit to an intensive care unit or specialized unit with dermatology consultation 7, 8. DRESS syndrome carries approximately 10% mortality, primarily from visceral organ compromise 9.
Diagnostic Workup
Perform comprehensive evaluation to confirm DRESS and assess organ involvement:
- Complete blood count with differential: Look for eosinophilia (often >1,000 cells/μL) and atypical lymphocytosis 7
- Comprehensive metabolic panel: Assess liver function (transaminases, bilirubin) and renal function (creatinine, BUN) 7, 1
- Urinalysis: Evaluate for associated nephritis 7
- Blood cultures if febrile: Rule out infectious etiology 7
- Total body skin examination: Document extent of rash, check ALL mucous membranes, assess body surface area involvement 7
- Serial clinical photography: Track progression or improvement 7
- Skin biopsy: If diagnosis uncertain, to differentiate from Stevens-Johnson syndrome, toxic epidermal necrolysis, or other severe cutaneous reactions 7
Immunosuppressive Treatment
Systemic Corticosteroids
Initiate IV methylprednisolone 0.5-1 mg/kg daily for moderate cases, or 1-2 mg/kg daily for severe presentations with significant organ involvement 7. The evidence from immune checkpoint inhibitor-induced DRESS provides the most specific guidance available for DRESS management.
- Convert to oral corticosteroids once clinical response is achieved
- Taper slowly over at least 4 weeks minimum 7
- Prolonged immunosuppression may be necessary—DRESS can require extended treatment compared to other drug reactions 7
Important consideration: Unlike Stevens-Johnson syndrome where corticosteroids are traditionally avoided, DRESS involves T-cell immune-directed toxicity that warrants and requires adequate immunosuppression 7.
Second-Line Agents for Steroid-Refractory Cases
If no improvement with corticosteroids or severe presentation:
- IVIG (intravenous immunoglobulin): Consider in severe or steroid-unresponsive cases 7
- Cyclosporine: Alternative immunosuppressant option 7, 2
- Plasma exchange: May be beneficial in severe cases with coagulopathy 10
Supportive Care
- Fluid and electrolyte management: Maintain balance, minimize insensible losses 7
- Topical therapy: High-potency topical corticosteroids, emollients (petrolatum-based), oral antihistamines for symptomatic relief 7
- Infection prevention: Critical given immunosuppression and skin barrier compromise 7
- Pain management: Consider palliative care consultation for severe cases 7
Monitoring and Specialist Consultation
- Dermatology: Essential for diagnosis confirmation and management guidance 7, 8
- Hepatology: If significant liver dysfunction develops (valproic acid carries additional hepatotoxicity risk) 1, 3, 11
- Nephrology: If renal involvement present
- Ophthalmology, otolaryngology, urology, gynecology: As needed for mucous membrane involvement 7
Long-Term Considerations
Seizure Management
- Continue brivaracetam at current dose for seizure control 6
- Consider alternative antiepileptic drugs if additional therapy needed—avoid aromatic anticonvulsants (phenytoin, carbamazepine, phenobarbital) which have high cross-reactivity risk 8, 12
- Levetiracetam is generally safe but monitor closely given one case report of lamotrigine DRESS with concurrent valproate 10, 11
Permanent Contraindication
Never rechallenge with valproic acid—the patient has a permanent contraindication to all valproate formulations (divalproex sodium, valproic acid, sodium valproate) 1.
Follow-Up
- Close monitoring for DRESS relapse (occurs in approximately 12% of cases) 13
- Avoid patch testing or drug provocation testing until at least 6 months after resolution and at least 1 month off systemic corticosteroids 13
- Document allergy prominently in medical record
Key warning: DRESS syndrome can progress despite drug discontinuation in some cases 1. Vigilant monitoring for worsening organ dysfunction is essential even after stopping valproic acid.